EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs

Ngo Cheung

Frontiers in Psychiatry · 17.03.2026 · 17

DOI: 10.3389/fpsyt.2026.1751605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 17.03.2026. Verfasst von Ngo Cheung. Beteiligte Einrichtung: Cheung Ngo Medical Limited, Hong Kong, Hong Kong SAR, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid-acting antidepressants show that mood can lift within hours when glutamatergic circuits shift from an “NMDA-dominant” to an “AMPA-dominant” state. Intravenous ketamine achieves this flip but is hampered by dissociation and logistics, while dextromethorphan + bupropion (Auvelity ® ) primarily supplies the initial NMDA blockade and yields slower, less durable benefit. We hypothesize that a fully oral, low-cost, four-component regimen may be able to approximate ketamine’s full plasticity cascade (1) dextromethorphan (DXM) for NMDA antagonism; (2) a potent CYP2D6 inhibitor (fluoxetine, paroxetine, or high-dose duloxetine) to prolong DXM exposure; (3) piracetam as an AMPA positive allosteric modulator; and (4) micronized L-glutamine to restore presynaptic glutamate pools and buffer against excitotoxicity. Preclinical evidence supports mechanistic synergy along the same axis, but the full combination remains untested in humans. This hypothesis warrants formal preclinical and clinical evaluation.

Schlagwörter

Stichwörter der Autor:innen

CYP2D6-inhibiting antidepressantsDXMdepressionglutamatergicglutamineketaminepiracetam

Autor:innen und Institutionen

  • Cheung Ngo Medical Limited, Hong Kong, Hong Kong SAR, China.

Zitieren

APA

Cheung, N. (2026). DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1751605

Vancouver

Cheung N. DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1751605

BibTeX
@article{Cheung2026,
  author = {Cheung, Ngo},
  title = {DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs},
  journal = {Frontiers in Psychiatry},
  year = {2026},
  volume = {17},
  doi = {10.3389/fpsyt.2026.1751605}
}
Kostenlos starten →